SIRT1 and SIRT2: emerging targets in neurodegeneration
Article first published online: 18 FEB 2013
Copyright © 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
EMBO Molecular Medicine
Volume 5, Issue 3, pages 344–352, March 2013
How to Cite
Donmez, G. and Outeiro, T. F. (2013), SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med, 5: 344–352. doi: 10.1002/emmm.201302451
- Issue published online: 5 MAR 2013
- Article first published online: 18 FEB 2013
- Manuscript Accepted: 16 JAN 2013
- Manuscript Revised: 15 JAN 2013
- Manuscript Received: 4 JAN 2013
- Funded Access
- Alzheimer's disease;
- Parkinson's disease;
Sirtuins are NAD-dependent protein deacetylases known to have protective effects against age-related diseases such as cancer, diabetes, cardiovascular and neurodegenerative diseases. In mammals, there are seven sirtuins (SIRT1-7), which display diversity in subcellular localization and function. While SIRT1 has been extensively investigated due to its initial connection with lifespan extension and involvement in calorie restriction, important biological and therapeutic roles of other sirtuins have only recently been recognized. Here, we review the potential roles and effects of SIRT1 and SIRT2 in neurodegenerative diseases. We discuss different functions and targets of SIRT1 and SIRT2 in a variety of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's Disease (HD). We also cover the role of SIRT1 in neuronal differentiation due to the possible implications in neurodegenerative conditions, and conclude with an outlook on the potential therapeutic value of SIRT1 and SIRT2 in these disorders.